Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055736 | 0.87 | GRM5 (0.51) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 | |
| SCHEMBL1081104 | 0.81 | GRM5 (0.50) | KDM4EGRM5ALDH1A1TDP1GAA | |
| SCHEMBL25941813 | 0.81 | KDM4E (0.61) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 | |
| SCHEMBL12467159 | 0.80 | KDM4E (0.60) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 | |
| SCHEMBL8214427 | 0.80 | KDM4E (0.60) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 | |
| SCHEMBL14307941 | 0.80 | KDM4E (0.60) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 | |
| SCHEMBL1011158 | 0.80 | TDP1 (0.63) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 | |
| SCHEMBL1077910 | 0.78 | LMNA (0.49) | KDM4EGRM5TDP1ESR2KMT2A | |
| SCHEMBL23728468 | 0.78 | LMNA (0.66) | KDM4EAPOBEC3AAPOBEC3GALDH1A1TDP1 | |
| SCHEMBL29019489 | 0.78 | KDM4E (0.57) | KDM4EAPOBEC3AAPOBEC3GGRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2831074-B1 | NOVEL PYRAZOLOPYRIMIDINES AS METABOTROPIC GLUTAMATE 5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9029360-B2 | Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| EP-2831074-A1 | NOVEL PYRAZOLOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| US-20130261105-A1 | NOVEL PYRAZOLOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| WO-2013144172-A1 | NOVEL PYRAZOLOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7947689-B2 | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-05-24 | — | — | US | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
| EP-2054421-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| WO-2008015270-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | KDM4E 1101/4885APOBEC3A 4390/4885APOBEC3G 4336/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | KDM4E 1357/4885APOBEC3A 4496/4885APOBEC3G 4444/4885 |
| US-20130261105-A1 | NOVEL PYRAZOLOPYRIMIDINES | GRM5, GRIK5, GRM2 | KDM4E 2330/4885APOBEC3A 4708/4885APOBEC3G 4593/4885 |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM3, GRM1 | KDM4E 1834/4885APOBEC3A 4149/4885APOBEC3G 3847/4885 |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | KDM4E 1401/4885APOBEC3A 4259/4885APOBEC3G 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.